

**Amendments to the Claims**

Please amend this application as follows:

**Amendments to the Claims**

1-12. (Cancelled)

13. (Previously presented) A method of treating myocardial infarction, comprising administering an effective amount of a compound selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1 derivatives to a patient in need thereof.

14. (Previously presented) The method of claim 13, wherein the compound is administered at a dose between 0.25 and 6 pmol/kg/min.

15. (Previously presented) The method of claim 14, wherein the dose is between 0.5 to about 2.4 pmol/kg/min.

16. (Previously presented) The method of claim 15, wherein the dose is between 0.5 to about 1.2 pmol/kg/min.

17-20. (Cancelled)

21. (Previously presented) A method of reducing mortality and morbidity after myocardial infarction, comprising administering to a patient who is incapable of autoregulation of blood glucose, a compound selected from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives, and pharmaceutically-acceptable salts thereof, at a dose effective to normalize blood glucose and by an administration method that maintains normal glucose levels.

22. (Cancelled)

23. (New) The method of Claim 13 wherein the compound is administered in a pharmaceutical composition comprising a buffer and a preservative at a dose effective to normalize blood glucose.